ABSTRACT
Introduction
Most patients are anxious, afraid or agitated while waiting for surgery. (1, 2) This can lead to significant stress and adversely influence anesthetic induction, and often leads to a poorer recovery after surgery. (3) (4) (5) Anxiety can also decrease patient's satisfaction with the perioperative experience. (6) The most important drugs for premedication are benzodiazepines, opioids, alpha-2 adrenoreceptor agonists, melatonin, dexmedetomidine or other drugs which have an anxiolytic, analgesic or sedative effect. (7, 8) Sedative premedication can be administered orally, intramuscularly, intravenously, rectally, sublingually or nasally. Oral or sublingual application does not hurt, but it may have a slow onset or the medication may be spit out. Drug taste is the main determinant for the success of their administration. Intramuscular medications may hurt and may result in a sterile abscess. Intravenous medications may be painful during injection or at the start of the infusion. Rectal medications, which are mostly used for children, may sometimes make the children feel uncomfortable and they may cause defecation, and occasionally burns. Nasal medications can be irritating, although their absorption is rapid. The choice of best premedication route and drug must be adapted to each patient. (9) The ideal agent should have a rapid onset, a predictable duration of action and enable rapid recovery. Midazolam, a sedative from the benzodiazepines group, has most of the above attributes and is most frequently used for premedication before anesthesia. (7, (10) (11) (12) (13) Its advantage is good bioavailability regardless of route of application, such as intravenous, intramuscular or transmucosal (oral, intranasal, rectal or sublingual). The sublingual route of administration for some medications is a good choice because of good pharmacokinetic properties and simple application without pain. One advantage of this route of application is avoidance of the first pass effect and an increase in bioavailability of the drug and thus more predictable pharmacological effects. (14, 15) Sublingual administration of the parenteral soluble form of midazolam was investigated in many previous studies, especially in children and just a few studies have described sublingual application of oral midazolam tablets. (16) The aim of this study was to investigate clinical efficacy and potential side effects of sublingual application in comparison with intravenous application of midazolam used for premedication.
Methods
Ethical approval for this study (Ethical Committee N° 25-1:3160-6/2012) was provided by the Ethical Committee of Clinical Hospital Centre Osijek, Osijek, Croatia (Chairperson Anto Rašić) on 18 th April, 2012. It was a prospective, randomized, controlled, single-blinded investigation. The studied population included 140 patients undergoing elective orthopedics, abdominal, urologic, maxillofacial or thoracic surgery, who were due to receive midazolam as a premedication. The main inclusion criteria included ASA (American Society of Anesthesiologists) physical status class I or II and older than 18 years of age. Exclusion criteria were an ASA physical status of class III or higher, patients with psychiatric disorders, and those taking antipsychotics, chronic use of benzodiazepines, and allergy to midazolam. The patients were randomized into one of two groups. One group (intra venous group) received 2.5 mg of Midazolam intravenously (Roche Dormicum, 15 mg/3mL ampulla) and the other group (sublingual group) of patients received 1/4 of a midazolam oral tablet (approximately 3.75 mg; Roche Dormicum, 15 mg tablets) sublingually (s.l.). The dose of ¼ midazolam tablet was clinically estimated as the amount needed for adequate premedication, and was relatively comparable with 2.5 mg of midazolam administered intravenously (i.v.), which is the mostly frequently used dose for premedication for the average patient. In the sublingual group, the tablet was placed under the tongue and patients were instructed not to swallow the tablet. Assessments were carried out before and after midazolam administration by an anesthesiologist who did not know about the administration route. Anxiety and sedation were evaluated using the Ramsey sedation scale (table 1) . A baseline sedation score was noted by a researcher prior to drug administration. Then the patients were observed at an interval of 10, 20 and 30 minutes after drug administration in the surgical holding areas. At the end of the study, the patients in both groups were asked about side effects and amnesia. Also, the investigator noted demographic data and data about surgery and type of anesthesia. All data were entered in a database, and analyses were done with SPSS 17.0 statistical programme. Most of the data are reported as mean ± SD or percentage (%). Differences between groups were analyzed using Chi-square or unpaired Student's t-tests. P was considered statistically significant if p < 0.05.
Results
This analysis identified epidemiological and clinical characteristics of two different applications of midazolam premedication at the Department of Anesthesiology, Resuscitation and Intensive Care Unit (ICU), University Hospital Osijek in Croatia. The study included 140 patients who underwent some kind of surgery, with six patients excluded due to chronic use of antipsychotics, benzodiazepines or other psychotropic drugs. Epidemiological data for each group were described in table 2. There were no statistically significant differences between the groups for most of the tested demographic variables except height (p=0.034). The studied population consisted of 83.57 % (117/140) orthopedics patients and 14.28 % (20/140) abdominal surgery patients. The rest included one urological, one thoracic and one maxillofacial patient. Also, 60 % (84/140) of operations were conducted under spinal anesthesia, 20.7 % (29/140) under general anesthesia and 19.3 % (27/140) using ultrasound guided regional nerve blocks, and there was no statistical difference 
Discussion
Most patients are anxious or afraid before anesthesia and surgery and they require some kind of premedication.
We conducted this study to show the benefits of sublingual administration of midazolam tablets for premedication. Like most studies, we found that only 25 % of patients seemed relatively calm, and more than 72 % of surgical patients had fear or anxiety before interventions. Therefore, premedication before anesthesia is necessary to alleviate anxiety, to facilitate smooth induction of anesthesia and to inhibit autonomic There is one study which compared intravenous and sublingual midazolam application. In this study Odou's et al. in France showed no significant differences between pharmacokinetic parameter values after intravenous (0.5 mg solution) and sublingual administration (0.5 mg tablet) in six rabbits. (24) In our study with 140 patients, clinical comparison was made between the sublingual and intravenous application of midazolam used as premedication before some surgical interventions. Each group was studied for sedation scores after midazolam application and for possible unwanted effects and amnesia after surgery. There was no significant difference in most demographic variables except in height between these two groups. After clinically assessing sedation levels, we found that sublingual application of midazolam had a sedative effect which is comparable with intravenous. We did not find a significant difference in baseline sedation scores before premedication between the groups. Although ten minutes after midazolam application both groups had satisfactory Ramsey scores (RS 1-2), significantly more patients from the intravenous group had RS score 2 (p=0.000) due to direct application of the drug into blood. However, twenty minutes after premedication, most of the patients in the sublingual group had satisfactory sedation levels which ensured calm and quality induction of anesthesia. Only a few patients in the intravenous group had RS score 4 at the same time. Because of a slower increase in blood concentration in the sublingual group, RS score 4 was noted only 30 minutes after premedication. Thirty minutes after midazolam application the patients had reasonably deeper scores (RS 2-4), but without statistical differences between the groups (p=0.642). Also, none of the patients had an unacceptably deep level of sedation, higher then Ramsey score 4. Likewise, recent studies showed a rapid and good sedation effect after sublingual midazolam application due to very fast absorption across oral mucosa. (9, 15, 17, 20, 23) Gupta et al. found, in a population of 60 children, that the desirable level of sedation and separation before surgery was achieved earlier in the case of sublingual midazolam than the oral route. (23) Just a small percentage of the patients in both groups (17.9 %) had complete or partial anterograde amnesia after surgery. We can explain this with the small doses of midazolam used for premedication. These doses provide satisfactory anxiolysis and good sedation but are most probably insufficient for amnesia development. About one third of the patients in the sublingual group complained about a bitter taste after tablet dissolving, and none of the patients in the intravenous group had unwanted side effects. We observed that female patients complained more often about tablet taste. After using midazolam tablets sublingually, we think that the only disadvantages are the taste and a large tablet dose which requires dividing the tablet into small parts. In the future, the pharmaceutical industry should consider developing special midazolam tablets for sublingual premedication with the appropriate dose and good taste. In our study, we did not investigate consumption of anesthetics and analgesics during anesthesia, nor postanesthesia recovery variables, but we clinically observed that there was no difference between these groups regarding recovery time after surgery. Also, we did not measure plasma levels of midazolam because of technical limitations and large costs. Finally, our intention in this study was also to show the cost-effectiveness of sublingual application of midazolam tablets. One tablet of 15 mg of midazolam costs about 0.30 Euro, and one ampoule of 15 mg of midazolam costs about 1.6 Euros. There is also the cost of needles and syringes for intravenous application. Therefore, sublingual application is cheaper than intravenous. This may not seem significant, but in hospitals that have a large number of surgical patients savings might be significant. In conclusion, sublingual application of an oral midazolam tablet reaches equivalent sedative effects compared with intravenous midazolam 20 minutes after administration but is associated with a bitter taste and less amnesic effect. Given the slower onset, difficulty for tablet dissolving (unreliable absorption), the unpleasant bitter taste, the possibility of administrative process induced anxiety and less amnesic effect, we cannot say sublingual administration is better than iv administration in adults.
